Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2848)	5/18/2010 12:57:50 PM
From: Jibacoa	Respond to of 3722

MYRX was up 9.65% and is still up 6.44% on volume of >70Ks still < 1/2 its ADV The stock made a double bottom at $4.02 which was the same L as yesterday.<g> bigcharts.marketwatch.com MYRX reported yesterday its 3rdQ results in which it was able to trim its loss for the 4th time on a roll, in spite of much lower revenue in the Q.<g> It said that it ended the Q with $148.4M and subsequently it received a payment of $12.7M from JAV pursuant to the termination of the proposed merger agreement. They said they were disappointed on JAV cancellation of the merger, but think they will be able to go forward on their own.<g> On June4-8 they expect to report results from two ongoing PIIs on Azixa (MPC-6827) in patients with metastatic melanoma in combination with temozolomide and in recurrent glioblastoma in combination with carboplatin, at the ASCO meeting in Chicago. This Yr, they expect to complete and to report final results of our PI investigating the safety, tolerability and pharmacokinetics of MPC-3100. In April they reported progress on multiple preclinical research programs, including: data characterizing MPI-0486348, their lead compound, at the AACR 101st Annual Meeting in Washington, D.C. and their IKK epsilon program at the Federation of American Societies for Experimental Biology meeting in Anaheim, CA. In February they reported results from two completed drug interaction P1 of MPC-4326, an small molecule inhibitor of HIV-1 maturation, at the 17th Conference on Retroviruses and Opportunistic Infections, in Frisco. The ACTAY is $5 The EL for the current Yr. is still around $2.14 vs. $2.42 last Yr. and further loss around $2.35 is expected for 2011. The stock has a good amount of resistance at the $4.50 level and it seems it will need some good news to make it to the $5 level.<g> bigcharts.marketwatch.com Bernard